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THE EFFECT OF GLUTAMINE ABSENCE ON THE VIABILITY OF 
ENDOTHELIAL CELLS WITH MTOR KNOCKDOWN GENES  
KRISTINA LI 
ABSTRACT 
BACKGROUND: Endothelial cells line the inner vessels of all organ systems. 
Endothelial cells share many similarities with cancer cells from their preference for 
glucose consumption even in the presence of oxygen availability (Warburg effect) to their 
incredibly fast proliferation through the mTOR pathway. Both cell types also rely heavily 
on glutamine, in addition to glucose, to maintain their metabolic activities. Glutamine is 
the most abundant free amino acid in the body, making it readily available to both 
endothelial and tumor cells as a source of carbons for the synthesis of biomass. Due to 
these overlapping similarities, there has become an interest in understanding how 
mutations of cells can allow them to survive in the absence of glutamine. A greater 
understanding of the mechanism of action from down regulation of specific genes can 
lead to many clinical applications.  
OBJECTIVE: To understand if down regulation of specific mTOR genes can affect the 
viability and proliferation of endothelial cells in glutamine deficient and glutamine 
supplemented media, respectively.  
METHODS: siRNA transfection was used as a secondary method to knock down specific 
genes in endothelial cell lines (ECFC and HUVEC). QPCR was used to validate 
knockdown efficiency. Cell progression was documented both visually and through cell 
	
	 vi 
counting over a long period of time. Cells were placed in both glutamine deficient and 
glutamine supplemented media to monitor mTOR activity and viability.  
RESULTS: Of all the genes tested, endothelial cells with CS, SLC7A11, WDR59, and 
WDR24 knockdowns were shown to have greater viability in glutamine deficient media 
than the controls. They were also shown to have suppressed proliferative behavior in 
complete media.  
CONCLUSIONS: Despite initial CRISPR screening results, not all of the knockdown 
genes selected from the list were able to survive in glutamine deficient conditions. 
However, we were able to show that knockdown of CS and SLC7A11 demonstrate 
similar viability in endothelial cells as previously published studies in cancer cells in 
glutamine deficient media. Interestingly, both GATOR2 complex genes (WDR59 and 
WDR24), which act as positive and negative regulators of the mTORC1 pathway via 
amino acid sensing, were able to survive without glutamine. Future studies could be done 
to understand the mechanisms behind their survival.   
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	 Shortly after 1628, when William Harvey first noted the mechanics of blood flow 
in the body, Marcello Malphigi uncovered the network of capillaries that he described as 
a barrier between blood and tissue.1 The endothelium was viewed as an inert membrane 
until the 1950’s when Palade and McGowan witnessed the interaction between the 
endothelium and lymphocytes in post-capillary venules. Since then, multiple studies have 
proven the endothelium as a dynamic, metabolically active organ that plays a pivotal role 
in vasomotor tone, inflammation, hemostasis, leukocyte adhesion, and barrier function.2  
 Endothelial cells (EC’s) line the inner wall of vessels of all organ systems, 
covering an approximate surface area of 4-7 m2 and weighing 1 kg in an average human.3 
They regulate flow of nutrients, blood cells, and active molecules through membrane-
bound receptors for proteins, lipid transporting particles, metabolites, and hormones. 
Most endothelial cells are quiescent, but upon perturbation from stimuli, such as 
inflammation or high stress, can rapidly proliferate and migrate and create a 
microprothrombotic environment. With these unique characteristics, endothelial cells also 
have peculiar metabolic activity. Diabetes and other vascular diseases can change the 
metabolism of EC’s and cause EC dysfunction.4  
 Despite lining the blood vessels and having direct access of oxygen, endothelial 
cells prefer to consume glucose via glycolysis rather than gain energy through 
mitochondrial oxidative phosphorylation.5 Glycolysis accounts for approximately 85% of 
total cellular generated ATP in endothelial cells, which is comparable to tumor cells. This 
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preference for aerobic glycolysis despite being in an oxygen dense environment is called 
the Warburg effect, and has been classically studied in the context of cancer cells.5,6 
Because of the similarities of endothelial cells and tumor cells, both in terms of their 
proliferative nature and metabolic preferences, there has been an interest in understanding 
more about the behavior and metabolic activity of EC’s as therapeutic targets.6, 7  
 The cellular reprogramming in cancer cells to prefer glycolysis to oxidative 
phosphorylation means that most of the glucose-derived carbons are being secreted as 
lactate despite oxygen availability.8 In addition to rapid glucose consumption, 
mammalian cells also require extracellular glutamine to survive and grow. Glutamine is 
used as the primary source of nitrogen for de novo biosynthesis of nucleotides and other 
nonessential amino acids. In addition, glutamine also satisfies two other demands in 
cellular metabolism: anaplerosis of oxaloacetate for the Krebs cycle, and generation of 
reductive NADPH power.9, 10 Glutamine is pumped into the cell via transporters to be 
used for biosynthesis or used by antiporters to push back out of the cell in exchange for 
other amino acids such as leucine or cystine. Once inside the cell, glutamine donates its 
amino group and the gamma position and is converted to glutamate by glutaminase. 
Glutamate is converted to alpha-ketoglutarate, a key intermediate of the Krebs cycle.11 It 
has also been shown in studies with cancer cells that reductive carboxylation can occur 
where alpha-ketoglutarate is carboxylated to citrate by isocitrate dehydrogenase as an 
important source of acetyl coA for fatty acid synthesis.12,13,14 Proliferating cells therefore 
use glutamine as a source for building proteins and nucleotides.  
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 Although there are many studies detailing the importance of glutamine for tumor 
cells, there have not been as many studies detailing glutamine metabolism in endothelial 
cells. Tumor cells have a high glycolytic rate because they use the carbons for biomass 
synthesis. However, it has been observed in endothelial cells that this is not the same 
case. In HUVECs, the ratio of glucose consumed to lactate produced is 1.74, indicating 
that approximately 90% of carbons entering the cell are turned over as lactate. Instead, 
isotope-tracing studies have shown that the large majority of carbons in the Krebs cycle 
are derived from glutamine8.  
 Despite the importance of glutamine for cell survival, there have been studies 
showing that certain cancer cell lines with specific gene knockdowns have compensatory 
mechanisms that allow them to survive in glutamine absent media. Ji Zhang et al 
discovered that knockdown of citrate synthase, the first enzyme of the Krebs cycle, 
prevented glutamine-withdrawal-induced apoptosis. Citrate synthase is responsible for 
the formation of citrate from acetyl-coA and oxaloacetic acid.15 Knockdown of citrate 
synthase redirected oxaloacetic acid into asparagine and aspartate biosynthesis. 
Knockdown of citrate synthase also had no effect on downstream mTOR signaling or 
autophagy. Therefore, asparagine synthetase, the enzyme that synthesizes asparagine 
from aspartate and glutamine, can prevent cell death in a glutamine-deprived 
environment. The knockdown of citrate synthase blocks the Krebs cycle and upticks 
formation of asparagine from oxaloacetic acid.16 Tumor cells undergo rapid apoptosis 
when glutamine dependent asparagine synthesis is suppressed. In a clinical context, acute 
lymphoblastic leukemia and T-cell lymphoma cells are unable to synthesize asparagine 
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on their own, relying heavily on high amounts of circulating asparagine. L-asparaginase, 
the enzyme that converts asparagine to aspartic acid and ammonia, is a drug that has 
shown clinical success as a therapy for childhood leukemia by depriving the leukemic 
cell of circulating asparagine and leading to cell death.17, 18, 19  
 Due to the large amounts of glutamine a cell intakes, once it is converted to 
glutamate it can also used as a substrate for antiport systems. In one example, the 
SLC7A11 gene encodes for a cystine/glutamate transporter. Called the xc- system, this 
transporter exports glutamate for cystine, the rate-limiting precursor for synthesis of 
glutathione. Approximately 1/3 to 1/2 of glutamine taken up in cultured human 
fibroblasts is used to drive import of cystine.20 Previously studied for its important 
antioxidant role, the xc- system has also proven to be an important metabolic regulator. 
Cells that have up-regulated xc- systems due to oxidative stress also have limited nutrient 
flexibility due to impaired glutamine metabolism, therefore making it more dependent on 
glucose. Due to the massive export of intracellular glutamate, an overexpressed xc- 
system dampens glutamate dependent processes such as mitochondrial respiration. When 
glucose is removed and glutamine becomes the dominant carbon source, tumor cells with 
this overexpression have limited viability.21 Physiologically, expression of SLC7A11 in 
tumor cells that have elevated levels of ROS has been linked to induction of tumor 
metastasis22,23 , resistance to cancer drugs24, and proliferation25-27. The xc- antiport has 
therefore been proposed as a therapeutic target for aggressive breast tumors. However, 
studies of cell metabolism have shown that knockdown of SLC7A11 in glucose-deficient 
conditions allows cells to better maintain intracellular glutamate levels, which is 
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converted into alpha-ketoglutarate and funneled into the Krebs cycle. This under 
expression allows enhanced survival with glutamine as the dominant carbon source.21  
 Although there have been many studies of tumor cell metabolism, there has not 
been a comparable number of studies for glutamine metabolism in endothelial cells. 
Given the overlap between cancer cell and endothelial cell metabolism, there is great 
potential for future clinical therapy development for disorders that occur when 
endothelial cells become mutated. This thesis attempts to identify genes that can survive 
in a glutamine-deprived environment, validate a subset of those genes using a secondary 
method, and elucidate future experiments that will help explain how pathways such as 










I: Cell Culture 
 
 Pooled human umbilical vein endothelial cells (HUVECs) and endothelial colony 
forming cells (ECFCs) were grown in 10 cm plates before splitting into 6-well plates for 
experiments. All plates were prepared with a gelatin (0.1% in diluted PBS) coat overnight 
to optimize cell-plate adhesion. Cells were kept in healthy conditions in M199 complete 
media (10% dFBS, penicillin/streptomycin, heparin, endothelial growth supplement) and 
changed every other day. 
 
II: siRNA 
 siRNAs were purchased from Sigma Aldrich and optimized using their Rosetta 
predictions algorithm for knockdown efficacy. siRNAs were diluted to 10 uM before 
added to Lipofectamine RNAiMAX Reagent and Opti-MEM media and transferred to 6-
well plate. Transfected cells were kept in Opti-MEM media for 6 hours after addition of 
siRNA mix and then replaced with M199 complete media. MISSION siRNA Universal 
Negative Control #1 (SIC001) was used as a control for every experiment. Product 
numbers from Sigma-Aldrich for each siRNA purchased is listed in the Appendix.  
  
III: Confirmation of siRNA knockdown 
 Successful knockdown of targeted genes was confirmed via qPCR analysis. On 
day two of siRNA transfection, each well of cells was mixed with 500 uL of Qiagen’s 
Buffer TCL and 5 uL of 2-Mercaptoethanol. Cells were gently scraped off, and 20 uL of 
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the mixture was deposited into a single well of TurboCapture 96 mRNA kit. Three wells 
were filled for each siRNA and gently shaken for 1 hour. Cycle values were downloaded 
from the RT-QPCR machine and data was analyzed using the delta-delta-CT method. 
 
IV: Proliferation assay 
 After siRNA, the knockdown cells were split into 6-well plates and seeded at 5% 
confluency in M199 complete media. Day one counting began the day after seeding, once 
cells had fully adhered to the bottom of the plate. Media was changed every other day, 
and the assay was stopped once cell counting was shown to plateau.  
 
V: Viability assay 
 Viability assays were tested at two different confluencies in an attempt to keep 
day one viability cell counts of siRNA control and remaining knockdowns as close as 
possible. In the first trial, cells after transfection were split into 6-well plates at 30% 
confluency and left in M199 complete media overnight to allow full cell attachment to 
wells. Afterwards, cells were changed to DMEM or M199 media without glutamine and 
day one counting began after a full 24 hours. In the second trial, siRNA transfection was 
applied directly to 80% confluent wells and counted, instead of splitting after 
transfection. 
 
VI: Cell counting 
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 Cells were trypsinized and diluted in cold DPBS, and samples of 20 uL were 
added to 20 uL of tryphan blue dye. 10 uL of the mixture was pipetted to a 
hemocytometer and inspected under a light microscope. Photos of the counting squares 
were taken and ran through a Python script created solely to count cells in the squares of 
interest and outputted onto an Excel spreadsheet. A full description of the Python script 
and its algorithms can be found in the Appendix I.  
 
VII: CRISPR screening 
 The CRISPR screen described below was performed by a post-doctorate student 
in the lab prior to this thesis. The protocol outlined by Shalem, et al was used to deliver a 
genome-scale CRISPR-Cas9 knockout library targeting ~20,000 genes28 to ECFC 
(passage 3) cells. The cells were kept in M199 media without glutamine for 2 weeks. The 
surviving cells after 2 weeks were rescued with M199 media with glutamine, and 
screened for which knockdown genes were able to survive. A biostatistician analyzed the 
results of the screen and ranked the surviving knockdown genes according to z-value. 
This resulted in a ranking of the knockout genes, from highest to lowest. In other words, 
the first listed gene would indicate the gene that survived in glutamine deficient media 
the best. To gain a better understanding of how knockout genes could relate to each other, 
the Database for Annotation, Visualization, and Integrated Discovery (DAVID) was 
used. When a list of genes is put into the database, it analyzes the list for the most 
common pathway that interconnects the most genes. When the top 500 and top 200 genes 
from the CRISPR screen were put into DAVID, the result was mTOR pathway for both 
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searches. This indicated that in glutamine deficient conditions, most of the cells that 









A CRISPR screening was performed by a post-doctorate student on passage 3 
ECFC cells targeting ~20,000 genes. The cells were placed in M199 media deprived of 
glutamine, and after two weeks there were a small but noticeable number of cells that had 
survived. The plates were replenished with M199 complete media for five days to 
encourage proliferation, and the remaining cells were screened for the knockout genes 




Figure 1 (left to right): cells in –Q media for 2 weeks at 10x magnification; 20x 
magnification; cells in +Q media for 5 days 
 
From the screen, statistical testing was done to understand which knockout genes 
were most prevalent in the dish after five days of proliferation. The top 500 hits and top 
200 hits were input into the Database for Annotation, Visualization, and Integrated 
Discovery (DAVID). From these results, the top pathway that came up in both searches 






	 A CRISPR screening was performed by a post-doctorate student on passage 3 
ECFC cells targeting ~20,000 genes. The cells were placed in M199 media deprived of 
glutamine, and after two weeks there were a small but noticeable number of cells that had 
survived. The plates were replenished with M199 complete media for five days to 
encourage proliferation, and the remaining cells were screened for the knockout genes 
that were able to survive. 
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was the mTOR pathway.  
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Figure 2: results of DAVID analysis using the first 500 (top) and 200 (bottom) hits 
from the CRISPR screen 
A second look was taken of the CRISPR screen hits, and I chose eleven genes in 
an attempt to reproduce results using a secondary method (siRNA). The eleven genes are 
a combination of mTOR genes and genes that were studied previously in cancer cells in a 




Figure 2: results of DAVID analysis using the first 500 (top) and 200 (bottom) hits 
from the CRISPR screen 
A second look was taken of the CRISPR screen hits, and I chose eleven genes in 
an attempt to reproduce results using a secondary method (siRNA). The eleven genes are 
a combination of mTOR genes and genes that were studied previously in cancer cells in a 




Table 1: list of mTOR complexes and genes. The first column indicates the knockout 
gene name. The second column indicates the numerical ranking of the gene 
knockdown in relation to its z-score. The third column indicates the positive z-score 
value. The chosen genes for testing are highlighted in yellow 
 In the first trial, pooled HUVECs were used to test the different siRNA’s in both 
their ability to proliferate and their viability to survive in glutamine deprived DMEM 
media. Observations of the cells were taking in the form of cell counting, and knockdown 
was confirmed using qPCR. Of the siRNA’s tested, only ATP6V1B1 had poor 
knockdown efficacy, and was confirmed via multiple trials. In the future, a different 
siRNA sequence should be purchased and retested. For example, the siRNA that we 
purchased from Sigma-Aldrich had a knockdown Targeted Gene Region of 1556, which 
means that the siRNA targets the region approximately 1556 nucleotides downstream 
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from the start of the Ref Seq sequence. An alternate transcript for this gene should be 
purchased and retested to get a better knockdown.  
 
Figure 3: qPCR analysis using the delta-delta-CT method showing insufficient 




Figure 4: qPCR analysis using the delta-delta-CT method showing sufficient 
knockdown of FLCN siRNA. 
 
Figure 5: qPCR analysis using the delta-delta-CT method showing sufficient 




Figure 6: qPCR analysis using the delta-delta-CT method showing sufficient 
knockdown of LAMTOR3 siRNA. 
 
 
Figure 7: qPCR analysis using the delta-delta-CT method showing sufficient 




Figure 8: qPCR analysis using the delta-delta-CT method showing sufficient 
knockdown of RRAGC siRNA. 
 
 
Figure 9: qPCR analysis using the delta-delta-CT method showing sufficient 




Figure 10: qPCR analysis using the delta-delta-CT method showing sufficient 
knockdown of WDR24 siRNA. 
 
Figure 11: qPCR analysis using the delta-delta-CT method showing sufficient 




Figure 12: qPCR analysis using the delta-delta-CT method showing sufficient 
knockdown of EIF4E2 siRNA. 
 
Figure 13: qPCR analysis using the delta-delta-CT method showing sufficient 
knockdown of RRAGA siRNA. 
The siRNA-transfected cells were reseeded into 6-well plates at 5% 
confluency for the proliferation assay and 30% confluency for the viability assay. 
Proliferation assays used M199 complete media with supplemental glutamine, while 
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viability assays used M199 media without glutamine. Cell counting was done by 
trypsinizing cells from one well/day and placing a sample into a hemocytometer. For 
proliferation assays, cell counting stopped when numbers began to plateau. For viability 
assays, cell counting stopped when control cells had all died out. 
 
Figure 14: proliferation and viability assay cell counts for EIF4E2 knockdown. 
 




Figure 16: proliferation and viability assay cell counts for LAMTOR2 knockdown. 
 




Figure 18: proliferation and viability assay cell counts for RRAGA knockdown. 
 
Figure 19: proliferation and viability assay cell counts for CS knockdown. 
 
Figure 20: proliferation and viability assay cell counts for SLC7A11 knockdown. 
The two genes citrate synthase and SLC7A11 were used as sanity checks, and the 
results from previous studies were reproduced in these trials. In glutamine-deprived 
conditions, knockdown of citrate synthase and SCL7A11 allowed cells to survive better 




Figure 21: proliferation and viability assay cell counts for RRAGC knockdown. 
 Due to both non-proliferative and overnight cell death upon seeding at 30% 
confluency, it is suspected that this RRAGC siRNA could be faulty or toxic to the cell. In 
the future, a different siRNA sequence should be purchased and retested. In other words, 
we are not sure if this toxic phenotype is a result of off-target effects of the specific 
siRNA purchased, or if knockdown of the RRAGC gene truly arrests cell proliferation in 
complete media. Because we also knocked down RRAGA, which is another component 
of the Rag complex, and we had normal proliferation I suspect that the problem lies with 




Figure 22: proliferation and viability assay cell counts for WDR24 knockdown. 
 
Figure 23: proliferation and viability assay cell counts for WDR59. 
 In the last two trials, experiments were repeated in ECFC’s and M199 media was 
used for glutamine deprivation to copy the original CRISPR pilot screen conditions as 
close as possible. These adjustments were made after the first trial due to media ordering 
constraints and backorders, but future testing should be kept as close to the original 
CRISPR screen as possible. 
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	 In the third trial, all siRNA’s were tested again but only for glutamine-deprived 
conditions. In an attempt to ensure that cell death was not occurring due to low 
confluency but was truly from glutamine deprivation, cells were seeded at 90-100% 
confluency, siRNA’d, and then put into M199 media without glutamine. In the first two 
trials, the siRNA’d cells were reseeded in complete media overnight to allow cell 
adhesion to the plate before glutamine deprivation. Because different gene knockdowns 
affect cell proliferation, cells were often not at the same confluency when switched to 
glutamine-deficient media. By seeding at a higher confluency before siRNA transfection 
and keeping the cells on the plate, the third trial attempted to remove low confluency as a 
potential factor contributing to cell death. This change in design also resulted in a 
survival timeline of almost two weeks, and therefore cell photographs were used to 
observe the viability assays.  
 




Figure 25: time course of siRNA CS cells in glutamine-deficient media. 
 




Figure 27: time course of siRNA FLCN cells in glutamine-deficient media. 
 




Figure 29: time course of siRNA LAMTOR3 cells in glutamine-deficient media. 
 




Figure 31: time course of siRNA RRAGC cells in glutamine-deficient media. 
 




Figure 33: time course of siRNA WDR24 cells in glutamine-deficient media. 
 
Figure 34: time course of siRNA WDR59 cells in glutamine-deficient media. 
As we can see from both the cell counts and visual recordings, some knockdown genes 
were better than others at surviving in glutamine deficient conditions. Specifically, 
SLC7A11, CS, WDR59, and WDR24 knockdowns fared better than siRNA control cells 
in glutamine deficient media. Gene knockdowns such as LAMTOR2, LAMTOR3, 
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RRAGA, RRAGC, EIF4E2, and FLCN did not survive as well in glutamine deficient 
conditions. Interestingly, there is an interesting link between genes that could not survive 
in the viability assay but proliferated normally in glutamine media. Likewise, there is a 
similar link between the genes that survived in glutamine deficient conditions yet could 
not proliferate as well in complete media. While previously published studies showed CS 
and SLC7A11 knockdowns are viable in glutamine deficient conditions for cancer cell 










	 Cellular growth is a fundamental biological process that is highly dependent on a 
cell’s environment. Nutrient availability within a local environment is sensed through 
central signaling pathways that communicate with multiple networks to increase cell size 
and number. A critical nutrient-sensing pathway is the mechanistic target of rapamycin 
(mTOR) pathway, which is a central regulator of cellular growth. Manipulation of this 
pathway can lead to diseases such as diabetes or cancer.4  
 In this thesis we showed that endothelial cells with certain mTOR knockouts were 
able to survive in glutamine deficient environments. A secondary method (siRNA 
transfection) was used to validate a smaller subset of the genes from the results of the 
CRISPR screen. Knockdown of genes such as CS and SLC7A11, which had been proven 
in previous studies to survive in glutamine deficient conditions of cancer cell lines16,21, 
was repeated with similar viability results in endothelial cells. Based on the similarities of 
cancer cell and endothelial cell metabolism, this could indicate that their abilities to 
survive in glutamine-deficient environments rely on the same mechanisms. 
 Despite knockdown of mTOR genes, certain genes were able to proliferate 
normally compared to the siRNA control cells. There was also an interesting overlap 
between knockdown genes that proliferated normally (based on cell counting) and their 
inability to survive in glutamine deficient conditions. These knockdowns included 
EIF4E2, FLCN, LAMTOR2, and LAMTOR3. These genes were observed to have a 
worse survival in glutamine-deficient media compared to control cells. Conversely, there 
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was a similar overlap with genes that could survive in glutamine deficient conditions but 
did not proliferate as well in complete media. These knockdowns include CS, SLC7A11, 
WDR24, and WDR59. It seems that certain gene knockdowns have a greater impact in 
mTOR signaling than others. From the qPCR data, there is also an indication that 
knockdown of certain gene expressions affect expressions of other genes in the mTOR 
pathway. Because the mTOR pathway is so extensive, it is possible that certain 
knockdowns trigger compensatory effects that still allow functionality of the mTOR 
pathway.  
 For knockdowns of genes that do decrease mTOR activity as evidenced by 
hindered proliferation, there are a few possible mechanisms that could explain their 
increased survival in glutamine-deprived conditions. In a previous study, it has been 
shown that the mTORC1 pathway inhibits macro pinocytosis, which allows for 
extracellular protein catabolism29,30. Inhibition of mTORC1 pathway therefore alleviates 
this suppression, allowing for better survival of cells. Knockdown of genes WDR24 and 
WDR59, which are part of the GATOR2 complex of mTORC131, was shown in this 
thesis to be viable in glutamine deficient conditions. This mechanism can be proven in 
future studies by applying a macro pinocytosis-inhibiting drug with siRNA knockdown, 
and recording any changes in viability.  
 Interestingly, it has been shown that the GATOR1 and GATOR2 complexes 
function as sensors of amino acid and determines whether mTORC1 is turned on or off. 
In low amino acid conditions, GATOR1 exerts GAP activity and keeps the downstream 
complex in the GDP-bound state, which does not allow mTORC1 to continue. In high 
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amino acid conditions, GATOR1 is inhibited by GATOR2 and the mTORC1 pathway is 
activated30. Other components of GATOR2 are also shown in the original CRISPR 
screen, although not retested using siRNA in this thesis. As shown in Table 1, SEH1L, 
MIOS, and SEC13 all show up on the screen, but they are ranked much further down.  
 A better understanding of how the mTOR pathway compensates for certain 
knockdowns and how inhibition of the mTOR pathway can affect cell survival can be 
translated to many clinical applications. Sirolimus, commonly known as rapamycin, is a 
drug that inhibits mTOR.32 In a specific example, rapamycin applied to coronary stents 
has been shown to block smooth muscle cell proliferation that could otherwise block the 
stented artery. Drug eluting coronary stents have been shown to shown to be statistically 
superior to bare metal stents to lowering future adverse cardiac events, especially 
restenosis. Interestingly, rapamycin coated stents have not shown the same efficacy in 
peripheral vasculature. In fact, rates of restenosis in the superficial femoral artery using 
bare metal stents was not statistically different from procedures using rapamycin coated 
stents (in-stent mean diameter at 6 months measured to be 4.76 mm+/- 0.54 mm and 4.94 
+/- 0.69 mm, respectively). 33 Clinicians have proposed various ideas such as plaque size, 
vessel size, and drug concentrations to address this anomaly. However, endothelial cell 
metabolism could play a role in why this drug has had varying success in preventing 
restenosis.  
 The variation of rapamycin drug efficacy extends to other clinical applications. 
Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease found in younger 
women, where the there is abnormal growth of smooth muscle cells and the mTOR 
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pathway is hyperactivated. A diagnostic biomarker of LAM is the identification of 
vascular endothelial growth factor D, and in 2015 the FDA approved rapamycin as a 
therapy for LAM. 34 Unfortunately, in a two year double-blind comparison study of 
rapamycin versus placebo, there was a statistically higher number of reported cases of 
adverse effects such as hypercholesterolemia, nausea, acneiform rash, and cardiovascular 
complications in patients taking rapamycin treatment. Unlike coronary artery disease 
where the rapamycin treatment wears off the drug eluting stent after some time, LAM is a 
chronic disease that requires lifelong treatment.35 Even if patients with LAM on treatment 
did not experience the above adverse side effects, long term use of rapamycin also has 
not been shown to be clinically safe.  
There are many known metabolic side effects of rapamycin such as 
hyperglycemia, hyperlipidemia, insulin resistance, and increased incidence of type 2 
diabetes. The metabolic defects caused by rapamycin remain unclear in their role of 
longevity and healthy aging.36 Clarification could pave way to understanding how 
rapamycin, and thus targeting mTOR, could be used in ways to maximize clinical 
treatment. For LAM patients, clinical trials are currently underway assessing the efficacy 
of combined inhibition of mTOR and autophagy.37 Because mTOR activated cells are 
dependent on glycolysis through the Warburg effect, suppression of glutamine 
metabolism and glycolysis could also be key.38  
 Notably, even though we demonstrated the survival of endothelial cells with 
specific knockdowns in glutamine deficient conditions, there were also limitations to this 
thesis. There were certain siRNA genes that should be retested, such as ATP6V1B1 and 
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RRAGC, as discussed in the Results section. Due to certain media availability and 
backordering, the media used in the first two trials to conduct cell counting for viability 
assays were slightly different than the media used in the CRISPR screen. Although the 
medias were matched as closely as possible and the results of the viability assays came 
out to be fairly similar, future experiments should be kept as close as possible to the 
original testing conditions.  
 In this thesis, we selected genes that were mostly in the mTOR pathway because 
it seemed most relevant to the top CRISPR screen hits. However, it would also be 
advantageous to do a secondary screen on the top ten hits of the CRISPR screen, 
regardless of which pathway they may belong it. Given that the top ten hits should 
indicate that they are the knockout genes that allow endothelial cells to best survive in 
glutamine deficient conditions, it would be interesting to elucidate the mechanism behind 








Appendix I: Cell Counting Algorithm: 
 Manual hand counting of cells is tedious and error-prone. It can fluctuate from 
person to person, and can become inconsistent as the cell counts become higher. 
To reconcile these issues with the large volume of cell counting required in these 
experiments, a Python script was created to automatically isolate and count cells in a 
specific region of interest of the hemocytometer. 
 After preparing the cell samples which are inserted under a glass slide on the 
hemocytometer, a photograph is taken of the four areas of the hemocytometer which cells 
are counted and averaged together. The Python script reads the image on a greyscale, and 
blurs the background through a Gaussian filter to adjust for varying levels of light. 
Because the microscope is shared among other labs and is manually adjusted, this filter 
ensures that the algorithm is robust as illumination settings will be different from day to 
day.  
 The hemocytometer has many intersecting lines that create different rectangles 
and squares. The Canny edge detector algorithm was implemented to isolate the region of 
interest for cell counting. Canny edge calculates the gradient magnitudes and directions 
of every single pixel of the image. Magnitude will indicate whether or not there is an 
edge; a high gradient magnitude indicates a color change, which indicates an edge, and a 
low gradient magnitude indicates the opposite. The gradient orientation indicates in 
which direction the edge lies (eg, top right corner to bottom). It also suppresses any non-
maximum values to eliminate any noisy responses to the edge detection. Hough’s 
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probabilistic line transform is then used to identify the specific lines that make up the 
outer edges of the 4x4 square box.  
After detection of the square of interest, the cells inside the square are detected 
from their brightness, surface area, circularity, convexity, and inertia. The output is a 
copy of the original image with the edges outlined and cells circled in red, with an Excel 
file that details the cell count with each image. Parameters were set after running the 
script on a batch of images and adjusting from repeated tests and feedback. 
 
Figure 36: (left) input file into Python script; (right) output file of Python script, 
clearly marking region of interest and indicating cells counted circled in red. The 
number of identified cells and file name were automatically recorded on an Excel 




Appendix 2: siRNA product number list: 
 siRNA efficacy can vary depending on the type and company siRNA’s are 
purchased from. For the sake of future reproducibility experiments, the siRNA product 
numbers are listed below. All siRNA’s were purchased from Sigma Aldrich.  
siRNA ID Sequence start 
ATP6V1B1 SASI_Hs01_00098246  1556 
WDR59  SASI_Hs01_00151462  1278 
WDR24 SASI_Hs01_00122968  1433 
LAMTOR2 SASI_Hs01_00089019  254 
LAMTOR3 SASI_Hs01_00208193  572 
RRAGA SASI_Hs01_00099501  371 
RRAGC SASI_Hs01_00190647  512 
FLCN SASI_Hs01_00238665 1122 
CS SASI_Hs01_00211136  759 
EIF4E2 SASI_Hs01_00062918 668 
SLC7A11 SASI_Hs02_00345461  1079 
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